FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:232-238 January 15, 2004 Number 3 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Lange, R. A. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel is unknown.

Methods We enrolled 2159 patients with coronary artery disease who underwent a percutaneous coronary intervention: 1079 patients were randomly assigned in a double-blind manner to receive abciximab and 1080 patients to receive placebo. All patients were pretreated with a 600-mg dose of clopidogrel at least two hours before the procedure. The primary end point of the trial was the composite of death, myocardial infarction, and urgent target-vessel revascularization within 30 days after randomization.

Results The incidence of the primary end point was 4 percent (45 patients) in the abciximab group, as compared with 4 percent (43 patients) in the placebo group (relative risk, 1.05; 95 percent confidence interval, 0.69 to 1.59; P=0.82). Most adverse events were myocardial infarctions: the incidence was 4 percent (40 patients) in the abciximab group and 4 percent (41 patients) in the placebo group (P=0.91). Twelve patients (1 percent) in the abciximab group and eight patients (1 percent) in the placebo group had major bleeding complications (P=0.37). Profound thrombocytopenia occurred in 10 patients (1 percent) in the abciximab group but in none in the placebo group (P=0.002).

Conclusions Our data suggest that in patients at low-to-intermediate risk who undergo elective percutaneous coronary intervention after pretreatment with a high loading dose of clopidogrel, abciximab is associated with no clinically measurable benefit within the first 30 days.

Source Information

From Deutsches Herzzentrum, Munich, Germany (A.K., J.M., H.S., C.V., M.G., A.S.); First Medizinische Klinik rechts der Isar, Munich, Germany (J.D., H.B., A.S.); Medizinische Klinik I, Garmisch-Partenkirchen, Germany (F.D.); St. Antonius Ziekenhuis, Nieuwegein, the Netherlands (J.M.B.); Herz-Zentrum, Bad Krozingen, Germany (F.-J.N.); and the Mayo Clinic, Rochester, Minn. (P.B.B.).

Address reprint requests to Dr. Kastrati at Deutsches Herzzentrum, Lazarettstr. 36, 80636 Munich, Germany, or at kastrati{at}dhm.mhn.de.

Full Text of this Article

This article has been cited by other articles:

• Dangas, G., Mehran, R., Guagliumi, G., Caixeta, A., Witzenbichler, B., Aoki, J., Peruga, J. Z., Brodie, B. R., Dudek, D., Kornowski, R., Rabbani, L. E., Parise, H., Stone, G. W., for the HORIZONS-AMI Trial Investigators, (2009). Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. J Am Coll Cardiol 54: 1438-1446 [Abstract] [Full Text]  
• Valgimigli, M., Campo, G., de Cesare, N., Meliga, E., Vranckx, P., Furgieri, A., Angiolillo, D. J., Sabate, M., Hamon, M., Repetto, A., Colangelo, S., Brugaletta, S., Parrinello, G., Percoco, G., Ferrari, R., for the Tailoring Treatment With Tirofiban in Pati, (2009). Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study. Circulation 119: 3215-3222 [Abstract] [Full Text]  
• Abdel-Latif, A., Moliterno, D. J. (2009). Antiplatelet Polypharmacy in Primary Percutaneous Coronary Intervention: Trying to Understand When More Is Better. Circulation 119: 3168-3170 [Full Text]  
• Mehilli, J., Kastrati, A., Schulz, S., Frungel, S., Nekolla, S. G., Moshage, W., Dotzer, F., Huber, K., Pache, J., Dirschinger, J., Seyfarth, M., Martinoff, S., Schwaiger, M., Schomig, A., for the Bavarian Reperfusion Alternatives Evaluati, (2009). Abciximab in Patients With Acute ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial. Circulation 119: 1933-1940 [Abstract] [Full Text]  
• Sibbing, D., Stegherr, J., Latz, W., Koch, W., Mehilli, J., Dorrler, K., Morath, T., Schomig, A., Kastrati, A., von Beckerath, N. (2009). Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30: 916-922 [Abstract] [Full Text]  
• Fung, A. Y., Saw, J., Starovoytov, A., Densem, C., Jokhi, P., Walsh, S. J., Fox, R. S., Humphries, K. H., Aymong, E., Ricci, D. R., Webb, J. G., Hamburger, J. N., Carere, R. G., Buller, C. E. (2009). Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.. J Am Coll Cardiol 53: 837-845 [Abstract] [Full Text]  
• Mahmud, E., Prasad, A. (2009). Optimal antiplatelet therapy during percutaneous coronary interventions includes glycoprotein IIb/IIIa inhibitors just eliminate the infusion.. J Am Coll Cardiol 53: 846-848 [Full Text]  
• Iijima, R, Byrne, R A, Ndrepepa, G, Braun, S, Mehilli, J, Berger, P B, Schomig, A, Kastrati, A (2009). Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart 95: 107-112 [Abstract] [Full Text]  
• O'Riordan, J. M., Margey, R. J., Blake, G., O'Connell, P. R. (2009). Antiplatelet Agents in the Perioperative Period. Arch Surg 144: 69-76 [Abstract] [Full Text]  
• Kinnaird, T, Anderson, R, Hill, J, Thomas, M (2009). Bleeding during percutaneous intervention: tailoring the approach to minimise risk. Heart 95: 15-19 [Abstract] [Full Text]  
• Crea, F., Camici, P. G., De Caterina, R., Lanza, G. A. (2009). CHAPTER 17 Chronic Ischaemic Heart Disease. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Cuisset, T., Frere, C., Quilici, J., Morange, P.-E., Mouret, J.-P., Bali, L., Moro, P.-J., Lambert, M., Alessi, M.-C., Bonnet, J. L. (2008). Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders: A Prospective, Randomized Study. J Am Coll Cardiol Intv 1: 649-653 [Abstract] [Full Text]  
• Williams, D. O., Abbott, J. D. (2008). What to Do With Patients Receiving Long-Term Clopidogrel: Reload or Relax?. Circulation 118: 1219-1222 [Full Text]  
• Gumina, R. J., Yang, E. H., Sandhu, G. S., Prasad, A., Bresnahan, J. F., Lennon, R. J., Rihal, C. S., Holmes, D. R. Jr, Singh, M. (2008). Survival Benefit With Concomitant Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Therapy at Ad Hoc Percutaneous Coronary Intervention. Mayo Clin Proc. 83: 995-1001 [Abstract] [Full Text]  
• Kastrati, A., Neumann, F.-J., Mehilli, J., Byrne, R. A., Iijima, R., Buttner, H. J., Khattab, A. A., Schulz, S., Blankenship, J. C., Pache, J., Minners, J., Seyfarth, M., Graf, I., Skelding, K. A., Dirschinger, J., Richardt, G., Berger, P. B., Schomig, A., the ISAR-REACT 3 Trial Investigators, (2008). Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. NEJM 359: 688-696 [Abstract] [Full Text]  
• Dobesh, P. P., Phillips, K. W., Haines, S. T. (2008). Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. Am J Health Syst Pharm 65: S22-S28 [Abstract] [Full Text]  
• Nappi, J. (2008). Benefits and limitations of current antiplatelet therapies. Am J Health Syst Pharm 65: S5-S10 [Abstract] [Full Text]  
• Patrono, C., Baigent, C., Hirsh, J., Roth, G. (2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S [Abstract] [Full Text]  
• Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., Ansell, J. (2008). The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 299S-339S [Abstract] [Full Text]  
• Harrington, R. A., Becker, R. C., Cannon, C. P., Gutterman, D., Lincoff, A. M., Popma, J. J., Steg, G., Guyatt, G. H., Goodman, S. G. (2008). Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 670S-707S [Abstract] [Full Text]  
• Feit, F., Manoukian, S. V., Ebrahimi, R., Pollack, C. V., Ohman, E. M., Attubato, M. J., Mehran, R., Stone, G. W. (2008). Safety and Efficacy of Bivalirudin Monotherapy in Patients With Diabetes Mellitus and Acute Coronary Syndromes: A Report From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. J Am Coll Cardiol 51: 1645-1652 [Abstract] [Full Text]  
• Kereiakes, D. J., Gurbel, P. A. (2008). Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention. J Am Coll Cardiol Intv 1: 111-121 [Abstract] [Full Text]  
• Ndrepepa, G., Berger, P. B., Mehilli, J., Seyfarth, M., Neumann, F.-J., Schomig, A., Kastrati, A. (2008). Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions Appropriateness of Including Bleeding as a Component of a Quadruple End Point.. J Am Coll Cardiol 51: 690-697 [Abstract] [Full Text]  
• Roffi, M., Mukherjee, D. (2008). Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era?. Eur Heart J 29: 429-431 [Full Text]  
• Ndrepepa, G., Kastrati, A., Mehilli, J., Neumann, F.-J., ten Berg, J., Bruskina, O., Dotzer, F., Seyfarth, M., Pache, J., Dirschinger, J., Berger, P. B., Schomig, A. (2008). One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. Eur Heart J 29: 455-461 [Abstract] [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: 652-726 [Full Text]  
• Van de Werf, F. (2007). Dual antiplatelet therapy in high-risk patients. Eur Heart J Suppl 9: D3-D9 [Abstract] [Full Text]  
• Rao, S. V., Eikelboom, J. A., Granger, C. B., Harrington, R. A., Califf, R. M., Bassand, J.-P. (2007). Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 28: 1193-1204 [Abstract] [Full Text]  
• Eshaghian, S., Kaul, S., Amin, S., Shah, P. K., Diamond, G. A. (2007). Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease. ANN INTERN MED 146: 434-441 [Abstract] [Full Text]  
• Dudek, D., Dziewierz, A., Chyrchel, B., Polonski, L., Legutko, J., Dubiel, J. S. (2007). Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight). Eur Heart J Suppl 9: A25-A31 [Abstract] [Full Text]  
• Lee, C.-H., Low, A., Tai, B.-C., Co, M., Chan, M. Y., Lim, J., Lim, Y.-T., Tan, H.-C. (2007). Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study. Eur Heart J 28: 19-25 [Abstract] [Full Text]  
• Mixon, T. A., Dehmer, G. J. (2006). Drive-Through Angioplasty: Is It Safe or Necessary?. Circulation 114: 2578-2580 [Full Text]  
• Bertrand, O. F., De Larochelliere, R., Rodes-Cabau, J., Proulx, G., Gleeton, O., Manh Nguyen, C., Dery, J.-P., Barbeau, G., Noel, B., Larose, E., Poirier, P., Roy, L., for the Early Discharge After Transradial Stenting, (2006). A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation. Circulation 114: 2636-2643 [Abstract] [Full Text]  
• Gurbel, P. A., Bliden, K. P., Tantry, U. S. (2006). Effect of Clopidogrel With and Without Eptifibatide on Tumor Necrosis Factor-Alpha and C-Reactive Protein Release After Elective Stenting: Results From the CLEAR PLATELETS 1b Study. J Am Coll Cardiol 48: 2186-2191 [Abstract] [Full Text]  
• Hochholzer, W., Trenk, D., Bestehorn, H.-P., Fischer, B., Valina, C. M., Ferenc, M., Gick, M., Caputo, A., Buttner, H. J., Neumann, F.-J. (2006). Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement. J Am Coll Cardiol 48: 1742-1750 [Abstract] [Full Text]  
• Balian, V., Galli, M., Marcassa, C., Cecchin, G., Child, M., Barlocco, F., Petrucci, E., Filippini, G., Michi, R., Onofri, M. (2006). Intracoronary ST-Segment Shift Soon After Elective Percutaneous Coronary Intervention Accurately Predicts Periprocedural Myocardial Injury. Circulation 114: 1948-1954 [Abstract] [Full Text]  
• Hamdalla, H., Steinhubl, S. R. (2006). Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention. Eur Heart J Suppl 8: G20-G24 [Abstract] [Full Text]  
• Mehta, S. R. (2006). Clopidogrel in non-ST-segment elevation acute coronary syndromes. Eur Heart J Suppl 8: G25-G30 [Abstract] [Full Text]  
• Bertrand, M. E., Van Belle, E. (2006). Triple antiplatelet treatment in patients presenting with non-ST-segment elevation acute coronary syndromes. Eur Heart J Suppl 8: G59-G63 [Abstract] [Full Text]  
• de Araujo Goncalves, P, Seabra-Gomes, R, Teles, R, Almeida, M, Aguiar, C, Raposo, L, Ferreira, J, Pereira Machado, F (2006). Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry.. Heart 92: 1155-1156 [Full Text]  
• Bhatia, V K, Di Mario, C (2006). Darwin and the survival of the fittest in modern interventional cardiology. Heart 92: 1017-1018 [Abstract] [Full Text]  
• Bittl, J. A. (2006). The Future of an Illusion. J Am Coll Cardiol 47: 2380-2383 [Full Text]  
• Rasoul, S., Ottervanger, J. P., de Boer, M.-J., Miedema, K., Hoorntje, J. C.A., Gosselink, M., Zijlstra, F., Suryapranata, H., Dambrink, J.-H. E., van 't Hof, A. W.J. (2006). A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial. Eur Heart J 27: 1401-1407 [Abstract] [Full Text]  
• Stone, G. W., Aronow, H. D. (2006). Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. Mayo Clin Proc. 81: 641-652 [Abstract] [Full Text]  
• Steinhubl, S. R., Charnigo, R. (2006). Clopidogrel Treatment Prior to Percutaneous Coronary Intervention: When Enough Isn't Enough. JAMA 295: 1581-1582 [Full Text]  
• Kastrati, A., Mehilli, J., Neumann, F.-J., Dotzer, F., ten Berg, J., Bollwein, H., Graf, I., Ibrahim, M., Pache, J., Seyfarth, M., Schuhlen, H., Dirschinger, J., Berger, P. B., Schomig, A., for the Intracoronary Stenting and Antithrombotic, (2006). Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial. JAMA 295: 1531-1538 [Abstract] [Full Text]  
• Bavry, A. A., Lincoff, A. M. (2006). Is Clopidogrel Cardiovascular Medicine's Double-Edged Sword?. Circulation 113: 1638-1640 [Full Text]  
• Steinhubl, S. R., Berger, P. B., Brennan, D. M., Topol, E. J., for the CREDO Investigators, (2006). Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention. J Am Coll Cardiol 47: 939-943 [Abstract] [Full Text]  
• Alfonso, F. (2006). Pathophysiology of Stent Thrombosis: Platelet Activation, Mechanical Factors, or Both?. J Am Coll Cardiol 47: 1086-1087 [Full Text]  
• Colombo, A., Stankovic, G. (2006). The Value of Selectivity. J Am Coll Cardiol 47: 719-720 [Full Text]  
• Ben-Yehuda, O. (2006). Upstream/Downstream: Glycoprotein IIb/IIIa in Non-ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol 47: 538-540 [Full Text]  
• Mehilli, J., Dibra, A., Kastrati, A., Pache, J., Dirschinger, J., Schomig, A., for the Intracoronary Drug-Eluting Stenting to Abr, (2006). Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27: 260-266 [Abstract] [Full Text]  
• Smith, S. C. Jr, Feldman, T. E., Hirshfeld, J. W. Jr, Jacobs, A. K., Kern, M. J., King, S. B. III, Morrison, D. A., O'Neill, W. W., Schaff, H. V., Whitlow, P. L., Williams, D. O., Antman, E. M., Smith, S. C. Jr, Adams, C. D., Anderson, J. L., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Jacobs, A. K., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47: 216-235 [Full Text]  
• Smith, S. C. Jr, Feldman, T. E., Hirshfeld, J. W. Jr, Jacobs, A. K., Kern, M. J., King, S. B. III, Morrison, D. A., O'Neill, W. W., Schaff, H. V., Whitlow, P. L., Williams, D. O., Antman, E. M., Smith, S. C. Jr, Adams, C. D., Anderson, J. L., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Jacobs, A. K., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113: 156-175 [Full Text]  
• Herrmann, J. (2005). Peri-procedural myocardial injury: 2005 update. Eur Heart J 26: 2493-2519 [Abstract] [Full Text]  
• von Beckerath, N., Taubert, D., Pogatsa-Murray, G., Schomig, E., Kastrati, A., Schomig, A. (2005). Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112: 2946-2950 [Abstract] [Full Text]  
• Aazami, R. (2005). Initial Appraisal of Acute Coronary Syndromes. Journal of Pharmacy Practice 18: 377-393 [Abstract]  
• Huber, K., Caterina, R. D., Kristensen, S. D., Verheugt, F. W.A., Montalescot, G., Maestro, L. B., Werf, F. V. d., for the Task Force on Pre-hospital Reperfusion The, (2005). Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction. Eur Heart J 26: 2063-2074 [Full Text]  
• Giugliano, R. P., Braunwald, E. (2005). The Year in Non--ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol 46: 906-919 [Full Text]  
• Walsh, S J, Spence, M S, Crossman, D, Adgey, A A J (2005). Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. Heart 91: 1135-1140 [Abstract] [Full Text]  
• Dibra, A., Kastrati, A., Mehilli, J., Pache, J., Schuhlen, H., von Beckerath, N., Ulm, K., Wessely, R., Dirschinger, J., Schomig, A., the ISAR-DIABETES Study Investigators, (2005). Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients. NEJM 353: 663-670 [Abstract] [Full Text]  
• Schomig, A., Schmitt, C., Dibra, A., Mehilli, J., Volmer, C., Schuhlen, H., Dirschinger, J., Dotzer, F., ten Berg, J. M., Neumann, F.-J., Berger, P. B., Kastrati, A., for the Intracoronary Stenting and Antithrombotic, (2005). One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J 26: 1379-1384 [Abstract] [Full Text]  
• Bhatt, D. L. (2005). To Cath or Not to Cath: That Is No Longer the Question. JAMA 293: 2935-2937 [Full Text]  
• Ajzenberg, N., Aubry, P., Huisse, M.-G., Cachier, A., El Amara, W., Feldman, L. J., Himbert, D., Baruch, D., Guillin, M.-C., Steg, Ph. G. (2005). Enhanced Shear-Induced Platelet Aggregation in Patients Who Experience Subacute Stent Thrombosis: A Case-Control Study. J Am Coll Cardiol 45: 1753-1756 [Abstract] [Full Text]  
• Kelly, R V, Steinhubl, S (2005). Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Heart 91: iii16-iii19 [Full Text]  
• Chaves, A. J., Sousa, A. G.M.R., Eikelboom, J. W., Rankin, J. M., Kastrati, A., Mehilli, J., Schuhlen, H., Dibra, A., Pache, J., Schomig, A., von Beckerath, N., Bollwein, H., Dirschinger, J., Dotzer, F., Berger, P. P. (2005). Letters Regarding Article by Mehilli et al, "Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel" * Response. Circulation 111: e370-e371 [Full Text]  
• Hochholzer, W., Trenk, D., Frundi, D., Blanke, P., Fischer, B., Andris, K., Bestehorn, H.-P., Buttner, H. J., Neumann, F.-J. (2005). Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention. Circulation 111: 2560-2564 [Abstract] [Full Text]  
• Longstreth, K. L, Wertz, J. R (2005). High-Dose Clopidogrel Loading in Percutaneous Coronary Intervention. The Annals of Pharmacotherapy 39: 918-922 [Abstract] [Full Text]  
• Williams, D. O. (2005). Clopidogrel Pretreatment for Percutaneous Coronary Intervention: Double, Double, Dose in Trouble?. Circulation 111: 2019-2021 [Full Text]  
• Patti, G., Colonna, G., Pasceri, V., Pepe, L. L., Montinaro, A., Di Sciascio, G. (2005). Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 111: 2099-2106 [Abstract] [Full Text]  
• Kastrati, A., Schomig, A. (2005). Drug-Eluting Stents and In-Stent Restenosis--Reply. JAMA 293: 1855-1856 [Full Text]  
• O'Neill, W. W., Dixon, S. R., Grines, C. L. (2005). The year in interventional cardiology. J Am Coll Cardiol 45: 1117-1134 [Full Text]  
• Authors/Task Force Members, , Silber, S., Albertsson, P., Aviles, F. F., Camici, P. G., Colombo, A., Hamm, C., Jorgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., Urban, P., Stone, G. W., Wijns, W. (2005). Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26: 804-847 [Full Text]  
• Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramirez, C., Macaya, C. (2005). Raising the loading dose of clopidogrel: aiming at the proper target?: reply. Eur Heart J 26: 740-741 [Full Text]  
• Leopold, J. A., Antman, E. M. (2005). Dual Antiplatelet Therapy for Coronary Stenting: A Clear Path for a Research Agenda. Circulation 111: 1097-1099 [Full Text]  
• Gurbel, P. A., Bliden, K. P., Zaman, K. A., Yoho, J. A., Hayes, K. M., Tantry, U. S. (2005). Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study. Circulation 111: 1153-1159 [Abstract] [Full Text]  
• Claeys, M. J., Van der Planken, M. G., Bosmans, J. M., Michiels, J. J., Vertessen, F., Van Der Goten, P., Wuyts, F. L., Vrints, C. J. (2005). Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. Eur Heart J 26: 567-575 [Abstract] [Full Text]  
• Lansky, A. J., Hochman, J. S., Ward, P. A., Mintz, G. S., Fabunmi, R., Berger, P. B., New, G., Grines, C. L., Pietras, C. G., Kern, M. J., Ferrell, M., Leon, M. B., Mehran, R., White, C., Mieres, J. H., Moses, J. W., Stone, G. W., Jacobs, A. K., Endorsed by the American College of Cardiology Fou, (2005). Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare Professionals From the American Heart Association. Circulation 111: 940-953 [Abstract] [Full Text]  
• Farouque, H.M. O., Tremmel, J. A., Shabari, F. R., Aggarwal, M., Fearon, W. F., Ng, M. K.C., Rezaee, M., Yeung, A. C., Lee, D. P. (2005). Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices. J Am Coll Cardiol 45: 363-368 [Abstract] [Full Text]  
• (2004). Abciximab Adds No Benefit to Clopidogrel in Low- and Intermediate-Risk PCI. Journal Watch Cardiology 2004: 10-10 [Full Text]  
• Tang, W.H. W., Lincoff, A. M. (2004). Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Blockade: The Triad Revisited. Circulation 110: 3618-3620 [Full Text]  
• Mehilli, J., Kastrati, A., Schuhlen, H., Dibra, A., Dotzer, F., von Beckerath, N., Bollwein, H., Pache, J., Dirschinger, J., Berger, P. P., Schomig, A., for the Intracoronary Stenting and Antithrombotic, (2004). Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel. Circulation 110: 3627-3635 [Abstract] [Full Text]  
• Kandzari, D. E., Berger, P. B., Kastrati, A., Steinhubl, S. R., Mehilli, J., Dotzer, F., ten Berg, J. M., Neumann, F.-J., Bollwein, H., Dirschinger, J., Schomig, A., ISAR-REACT Study Investigators, (2004). Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 44: 2133-2136 [Abstract] [Full Text]  
• Porto, I, Blackman, D J, Nicolson, D, Niccoli, G, Kahn, F Z, Ormerod, O, Forfar, C, Channon, K, Banning, A P (2004). What is the incidence of myocardial necrosis in elective patients discharged on the same day following percutaneous coronary intervention?. Heart 90: 1489-1490 [Full Text]